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Abstract
Background: Distraction osteogenesis is the standard treatment for the management of lower
limb length discrepancy of more than 3 cm and bone loss secondary to congenital anomalies,
trauma or infection. This technique consists of an osteotomy of the bone to be lengthened,
application of an external fixator, followed by gradual and controlled distraction of the bone ends.
Although limb lengthening using the Ilizarov distraction osteogenesis principle yields excellent
results in most cases, the technique has numerous problems and is not well tolerated by many
children. The objective of the current study is to determine if Botulinum Toxin A (BTX-A), which
is known to possess both analgesic and paralytic actions, can be used to alleviate post-operative
pain and improve the functional outcome of children undergoing distraction osteogenesis.
Methods/Design:  The study design consists of a multi centre, randomized, double-blinded,
placebo-controlled trial. Patients between ages 5–21 years requiring limb lengthening or deformity
correction using distraction will be recruited from 6 different sites (Shriners Hospital for Children
in Montreal, Honolulu, Philadelphia and Portland as well as DuPont Hospital for Children in
Wilmington, Delaware and Hospital for Sick Children in Toronto, Ont). Approximately 150
subjects will be recruited over 2 years and will be randomized to either receive 10 units per Kg of
BTX-A or normal saline (control group) intraoperatively following the surgery. Functional outcome
effects will be assessed using pain scores, medication dosages, range of motion, flexibility, strength,
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mobility function and quality of life of the patient. IRB approval was obtained from all sites and
adverse reactions will be monitored vigorously and reported to IRB, FDA and Health Canada.
Discussion:  BTX-A injection has been widely used world wide with no major side effects
reported. However, to the best of our knowledge, this is the first time BTX-A is being used under
the context of limb lengthening and deformity correction.
Trial Registration: NCT00412035
Background
1. Lengthening and Deformity Correction
Lower extremity limb deformity and length discrepancy
can occur secondary to congenital anomalies (such as
fibular hemimelia or Blount's disease) or traumatic, infec-
tive or neoplastic events leading to partial or total physeal
arrest. If the discrepancy exceeds 3 to 5 cm, then equaliz-
ing limb length would be the ideal treatment [1].
Since the first bone lengthening procedure performed on
a human patient by distraction was reported by Codivilla
in 1905 [2], numerous techniques for lengthening bones
and correcting deformity have been developed, but these
were fraught with unacceptably high complication rates
[3]. Then the Russian orthopaedic surgeon Gavriel Ili-
zarov developed new principles in limb lengthening.
Working in the small Siberian community of Kurgan, he
found that after a delay of a few days following osteot-
omy, bone and soft tissue would regenerate when sub-
jected to slow and gradual distraction. He called this the
"Law of Tension Stress" or Distraction Osteogenesis (DO)
[4,5].
The treatment protocol, according to the Ilizarov distrac-
tion osteogenesis principle [4,5] consists of an osteotomy
of the bone followed by a latency phase of 5 to 7 days.
This is followed by the actual lengthening or distraction
phase which is continued until the desired amount of dis-
traction is obtained. The optimum amount of daily
lengthening has been found to be 1.0 mm, divided into 4
increments. For example, 5 cm of lengthening will require
50 days of distraction. This is followed by the consolida-
tion phase. This is the period for which the fixator has to
be left in place, until the newly created bone between the
osteotomy ends becomes biomechanically strong enough
to withstand the stresses of mechanical usage. This consol-
idation phase is very long and takes approximately 1
month for every cm lengthened. For example, a lengthen-
ing of 5 cm will require 5 months in the fixator.
Problems of Distraction osteogenesis
Limb lengthening and deformity correction using the Ili-
zarov technique [4,5] yields excellent results in most cases
[6-10]. However, the technique has numerous problems
[11,12] and is not well tolerated by many children. Some
of these problems include medical complications such as
pin site infections, pain, muscle-related complications
(including contractures, joint stiffness and subluxation),
oedema, osteoporosis of the lengthened segment, and
problems with the bony regenerate such as premature
fusion, delayed or non-union. Psychological disturbances
may occur during treatment and may necessitate treat-
ment. In addition, the financial burden to the family and
the health institution could be significant.
Numerous attempts have been and continue to be made
in order to minimize these complications by attempting
to accelerate the formation of new bone at the distracted
zone [13,14], so that the fixator could be removed at an
earlier date. However, to the best of our knowledge, none
of these studies focused on pain and muscle spasm or con-
tractures in an attempt to improve the outcome of the
lengthening procedure. We were able to find only one full
report addressing pain issues in limb lengthening [15]. In
this report, the type and amount of pain varied according
to the stage of the lengthening process, and occurred
throughout the entire process, which again emphasizes
the importance of pain as a major component of limb
lengthening procedures. Many aspects of the limb length-
ening or deformity correction process contribute to pain,
including [15]:
1. In the early stages, the corticotomy and incision sites
are painful.
2. Acute post-operative oedema contributes to pain.
3. Gradual distraction increases soft tissue tension, result-
ing in stretching pain sensation from the muscles.
4. Pin sites often become infected.
5. Physiotherapy in the form of range of motion exercises
and gait training may intensify already existing pain.
Effect of lengthening or correction on muscles
Skeletal muscles have a remarkable capacity for adapta-
tion to gradually increasing limb length or decreasing
deformity. Several mechanisms of muscular adaptation to
increasing length during distraction osteogenesis haveTrials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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been described [16,17]. The most important one is the
addition of new serial sarcomeres to lengthen existing
muscle fibers and to prevent sarcomere elongation
[16,17], which is very important for maintaining muscu-
lar function. However, it has been shown that bones and
muscles do not lengthen at the same rate [16]. When the
degree of muscle – tendon adaptation during limb length-
ening or deformity correction is not enough to adequately
accommodate the increase in bone length, muscle related
complications such as joint compression, bone growth
retardation, contractures and subluxation may occur.
Intensive physiotherapy, braces, readjustment of the fixa-
tor and even further surgical intervention may then be
required.
Another interesting issue to raise is whether or not length-
ening causes damage to skeletal muscle? Several studies
have shown that lengthening causes structural changes in
muscles. Signs of partial muscle denervation during
extremity lengthening in humans have been documented
by electromyography (EMG) findings [18,19]. Whether
this muscle damage documented by EMG findings recov-
ers or not, is controversial. Some authors believe in a per-
manent effect of extremity lengthening on the
neuromuscular tissues [20], while others believe that this
damage is temporary as evidenced by the appearance of
multiple polyphasic potentials [21]. Some authors
[21,22] also found in a canine model of distraction osteo-
genesis, selective atrophy of Type II muscle fibers (and to
a lesser extent Type I) and areas of muscle fiber necrosis
during the distraction period. They attribute the Type II
muscle fiber atrophy to muscle disuse. These events are
followed by increased muscle fiber density secondary to
muscle neogenesis.
The question then arises: Can BTX-A injection minimize
or even prevent muscle related complications and can it
prevent muscle damage during limb lengthening or
deformity correction?
2. Botulinum Toxin A
Botulinum toxins are extremely potent, naturally occur-
ring poisons. These toxins are fermentation products of
the anaerobic spore-forming bacterium Clostridium botuli-
num. Eight immunologically distinct botulinum serotypes
have been identified [23]. Of these, seven serotypes – A, B,
C1, D, E, F, and G – are neurotoxins. These toxins cause
flaccid paralysis by blocking acetylcholine (Ach) release,
which is required for muscle contraction, at the neu-
romuscular junction. Therefore, therapeutic benefit may
be obtained by exploiting the pharmacologic properties of
carefully administered regional application of this puri-
fied neurotoxin.
Types A and B are the only types used in clinical practice.
Type A is available in the United States as BTX-A (Allergan,
Inc., Irvine, Ca.) and in several other countries as Dysport
(Ipsen Ltd., Berkshire, UK). Type B is available in the
United States as Myobloc (Elan Pharmaceuticals' San
Diego, CA) and in European countries as NeuroBloc (Elan
Pharmaceuticals, San Diego, CA). Botox is available in a
vial that contains 100 units of toxin. The product is
shipped from the manufacturer on dry ice and is stored
either in the refrigerator at 2 to 8°C or in the freezer at -
5°C. Frozen vacuum-dried toxin is reconstituted with 0.9
ml normal saline to various concentrations usually 2.5 to
10 units/0.1 ml.
Although there are only four indications approved by the
FDA for the clinical use of BTX-A (cervical dystonia, stra-
bismus, facial hemispasm and blerephorospasm) [24-26],
the use of BTX-A has rapidly expanded beyond these
approved disorders and includes a variety of clinical con-
ditions where BTX-A is now being used both for its neu-
romuscular and analgesic effects [27-45]. The explosion of
interest in the biology and clinical applications of BTX-A
is reflected by the number of publications in the last few
years on the subject. A review of the literature (Pubmed)
revealed 5200 entries under the word botulinum injec-
tions.
Dosing parameters
The volume and concentration of BTX-A have been dis-
cussed at the American Academy of Cerebral Palsy and
Developmental Medicine (AACPDM) meeting in Septem-
ber 2003. Doses of 20 units/kg/day were reported [46]. It
was suggested that decreasing the concentration and
increasing the volume injected would be more beneficial.
However, a larger volume injected may have the side effect
of wider infiltration [47,48].
In two very interesting and most recent studies on the
safety profile and efficacy of BTX-A used in Europe (Dys-
port) in children with spasticity, Bakheit et al, [49,50]
reviewed the use of BTX-A in 758 children in 17 different
European Centres. The doses of BTX-A ranged from 5 to
18 units/Kg/day. Interestingly, they found that a dose of
10 units/Kg/day gave the optimal clinical results. Further-
more, their data suggest that BTX-A in excess of 1000 units
does not improve the therapeutic response and may
increase the risk of adverse events. (However, although
BTX-A and Dysport are both Botulinum toxin type A, their
doses cannot be compared).
Median Lethal dose
is estimated to be 3000 units of BTX-A for a 70-kg adult
[23].Trials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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Safety, Risks and adverse effects
BTX-A has been in use as a therapeutic agent since the late
1970s, and has been shown to be a remarkably safe drug
when used under medical supervision [51-61]. Since the
mechanism of action of BTX-A is so specific, non-neu-
romuscular side effects are uncommon and systemic
effects are very rare [23]. Side effects include a flu-like syn-
drome that is generally short-lived [62], dysphagia, and
dry mouth. Unintended weakness of the muscle injected
or of nearby muscles could also be a negative effect. Other
side effects include muscle soreness, rash, headaches,
light-headedness, fever, chills, hypertension, diarrhea and
abdominal pain [23]. In their review of 758 children with
chronic spasticity, Bakheit et al, [49,50] reported a 7 %
incidence of adverse effects. Another important finding of
their study was that the total dose of the toxin per treat-
ment session, rather than that calculated on the basis of
body weight, correlated with the incidence of adverse
events and also functional improvement or deterioration.
Antibody formation
All botulinum neurotoxins are proteins and therefore
immunoresistance may develop secondary to formation
of blocking antibodies. The incidence of antibody-medi-
ated resistance in long-term treated patients ranges from 3
to 23%, depending on the patient sample, treatment regi-
men and toxin preparation [51]. With the new BTX-A for-
mulation, (5 nanograms of neurotoxins per 100 units that
were introduced in 1997, less than 3 % of patients will
develop antibodies [51]. In a most recent study [24] eval-
uating 130 patients treated for cervical dystonia, 42 had
the original BTX-A used before 1998 (25 ng protein/100
units) and 119 had the current BTX-A injection (5 ng pro-
tein/100 units). None of the 119 patients who received
the new BTX-A injection developed antibodies while 9.5%
of those who received the old formulation developed anti-
bodies.
Antibodies against the toxin are presumed to be responsi-
ble for most cases of resistance [51]; however, other
potential risk factors for immunoresistance include
genetic predisposition, frequency of administration, and
possibly prior resistance to other botulinum toxin sero-
types [24]. Resistance may be minimized by using the
lowest effective dose with at least 3 months interval
between injections [51]. Patients who develop resistance
to one serotype may benefit from a switch to a different
serotype [51].
Administration
One ml "tuberculin" syringes with 27 – 32 gauge needles
are used for the injections. Electrical stimulation or ultra-
sound may be useful techniques to identify selected mus-
cles during BTX-A therapy but are rarely used. Most centres
do not use general anesthesia for the injections [50].
Mechanism of action
Botulinum toxins are known to have at least 3 mecha-
nisms of action: paralytic, anti-secretory and analgesic
(anti-nociceptive).
A. Paralytic effects
Botulinum toxin is a pre-synaptic neuromuscular block-
ing agent. It produces temporary chemical denervation by
blocking the release of acetylcholine, thus, causing muscle
relaxation. BTX-A acts on all cholinergic nerve terminals,
including those of motor neurons, preganglionic sympa-
thetic and parasympathetic neurons and postganglionic
parasympathetic nerves. The molecular mechanism of
inhibition of acetylcholine release is a multistep process
that has been very well described [51].
Muscle weakness occurs within a few days to 1 week after
local injection, peaks within 2 weeks for several weeks,
and then plateaus in milder form (the desired clinical
effect) before gradually returning to baseline [51]. The
effects of BTX-A are dose related. Recovery from the toxin-
induced paralysis involves resprouting of terminals from
the axon, followed by slow recovery of the neuron's ability
to release acetylcholine. The clinical effects last 3 to 4
months after each injection [51].
B. Anti-secretory effects
BTX-A blocks parasympathetic nerve-induced secretion
and may be useful in conditions of palmar and plantar
hyperhydrosis [40].
C. Analgesic (anti-nociceptive effects)
The analgesic effects of BTX-A are very intriguing and were
first reported in 1985 in a pilot study of BTX-A treatment
for cervical dystonia, characterized by abnormal, involun-
tary neck and shoulder muscle contraction and often
resulting in significant disabling pain [63]. It was noted in
that study that the most marked benefit of BTX-A injec-
tions was pain relief. Since then, numerous reports have
confirmed the analgesics effects of BTX-A.
The association between BTX-A and pain relief was origi-
nally thought to relate only to its effect on muscle contrac-
tion. However, the analgesic effects of BTX-A could not be
entirely explained by its muscle relaxation effects. Several
studies suggest that other pathways may also play a role in
the analgesic effects of BTX-A. The strong suspicion that
BTX-A has an anti-nociceptive action independent of its
paralytic effect developed because of several clinical
observations. First, in conditions of pathologic muscle
overactivity (dystonia and spasticity), pain relief often
begins quickly before weakness, seems greater than the
degree of weakness, and outlasts the weakness [63]. Sec-
ond, BTX-A has been shown to cause analgesia without
weakness in an animal model of neuropathic pain [64].Trials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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Third, BTX-A has been shown to block the formalin-
induced release of glutamate in the paws of rats [65] and
it is known that glutamate mediates the release of neuro-
transmitters substance P and calcitonin gene related pep-
tide (CGRP) which play a role in transmission of pain.
BTX-A also directly blocks the release of substance P and
CGRP [66,67]. Therefore, it seems that BTX-A exerts its
analgesic effects through several pathways:
i. Analgesic effect secondary to muscle relaxation
Many chemicals, including bradykinin, serotonin, potas-
sium, prostaglandin E2, and several neuropeptides such
as substance P, glutamate and CRGP can sensitize muscle
nociceptors. Because activation of these nociceptors may
be related to the degree of contraction of a muscle, BTX-A
may ameliorate pain simply by reducing the extent of
muscle spasm or contraction and, therefore, uncouple this
process [30]. Also, BTX-A may decrease pain due to mus-
cular spasm, by decreasing distortion of structures
attached within the muscles and also by decreasing the
compression of nerves as they pass within the muscle
[68].
ii. Analgesic effect secondary to inhibition of peripheral sensitization
BTX-A may have a direct effect on non-cholinergic neu-
rons and reducing peripheral sensitization. BTX-A inhibits
the release of the nociceptive or inflammatory neuropep-
tides substance P [66,67], and CRGP, directly or indi-
rectly, by inhibiting the release of glutamate, which in
turn stimulates the release of substance P (peripherally
and centrally) and CRGP. Substance P is a neuropeptide
that plays a role in pain perception, vasodilatation, and
neurogenic inflammation.
iii. Analgesic effect secondary to inhibition of central sensitization
Some studies suggest that BTX-A is transported by axons
to the CNS after intramuscular injection [68]. Many neu-
rotransmitters are released in vesicles by exocytosis mech-
anisms that are dependent upon the SNARE proteins,
which are the target of botulinum toxins. Therefore, BTX-
A blocks the release of more neurotransmitters than ACh,
and has been shown to affect neurotransmission in CNS
tracts that are involved in pain transmission or modula-
tion [68]. Changes in the central sensory system "neuro-
plasticity" secondary to pain stimuli could also be affected
by BTX-A [67].
iv. Analgesic effect through alteration of autonomic function
Blood flow is clearly related to inflammation and
ischemic pain and is probably involved in the sensitiza-
tion of nociceptors. Autonomic neurons alter regional
blood flow by controlling the smooth muscle walls of
small arterioles. BTX-A may block some of the autonomic
vascular control functions and at the same time may alter
the release of a variety of non-ACh agents that also affect
blood flow. Finally, autonomic function mediated by the
release of ACh is associated with both emotional behav-
iour and stress through complex CNS circuity. BTX-A may
alter the global perception of pain and or the patient's
overall response to pain through this linkage [67].
Although the analgesic properties of BTX-A could have tre-
mendous potential in a wide variety of clinical problems
[69-71]], we were able to find only one study on the
effects of BTX-A in relieving post-operative pain in ortho-
paedic procedures and none in the context of limb length-
ening. In a double-blinded, placebo controlled trial [72],
Barwood et al. reported profound anti-nociceptive activity
of BTX-A injection when administered prior to adductor-
release surgery in children with cerebral palsy. The analge-
sic effect was so dramatic that the trial was terminated
early. Children treated with BTX-A had a reduced need for
narcotic analgesics, were discharged earlier, and had bet-
ter outcomes than the placebo group.
The objective of the current multi centre clinical study is
to assess if the use of Botox does alleviate pain for children
in the early post op period during distraction osteogene-
sis. This protocol addresses the issues of both pain and
muscle spasm through the use of BTX-A injections.
Methods/Design
The design chosen to test our hypothesis and answer our
specific aims is a multi-center prospective, randomized,
double-blinded, controlled trial. The pilot study success-
fully demonstrated that recruitment, randomization and
data collection are feasible. In addition, the existence of
only one published report in the English literature dealing
with post-operative pain in children undergoing limb
lengthening [15] and the absence of any data on the use
of BTX-A injection for relief of pain in cases of distraction,
propel us to proceed with this design.
1. Sample and Duration of Study
Subjects will be recruited at each site from patients requir-
ing surgery for limb lengthening or deformity correction
using distraction with a fixator. The 6 sites participating in
the study include Shriners Hospital for Children in Mon-
treal, Honolulu, Philadelphia and Portland as well as
DuPont Hospital for Children in Wilmington, Delaware
and Hospital for Sick Children in Toronto, Ont. Based on
the historical data at each site for 2003–2006, estimations
were made of potential participants for each site. The
mean number of children treated for this problem at each
participating site varies from 8 to 30 for a total of approx-
imately 75 potential participants per year for the 6 sites.
The total sample size expected to meet the inclusion crite-
ria is approximately 150 subjects to be recruited over 2
years (See section 10 for a detailed power calculation).Trials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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Subjects will be randomized to either an injection of BTX-
A (BTX-A group) or normal saline (control group) and
both will continue with standard post-operative nursing
care and rehabilitation. Patients undergoing this particu-
lar intervention are closely followed in the outpatient
clinic after discharge. At each visit they routinely meet the
surgeon, the Care Coordinator, and the physical therapist.
The site coordinator will track the participants and ensure
that the standardized assessments are administered at the
appropriate visit.
Subjects will be enrolled during the first 24 months of the
3-year project. Each patient is followed for up to 12
months with data collected longitudinally over this
period. The last patients enrolled in year 2 will be fol-
lowed for 9–12 months into year 3. No recruitment will
occur in year 3, however, follow-up on the final patients
enrolled in year 2 will continue into the final months of
year 3. Analysis will commence in year 3. Depending on
the timing and number of participants enrolled in year 2
a continuation to year 4 may be required for final statisti-
cal analysis.
Inclusion Criteria
1. Age: 5 to 21 years.
2. Etiology of the deformity: congenital or acquired.
3. Amount of lengthening or deformity correction: any
amount.
4. Site of lengthening or deformity correction: lower
extremity, unilateral single segment.
5. Type of fixator: circular or uniplanar.
Exclusion Criteria
1. Children younger than 5 years of age.
2. Associated neuromuscular conditions that may hinder
weight bearing.
3. Individuals on aminoglycosides, as aminoglycosides
can potentiate the effect of Botulinum toxin A.
4. Neurofibromatosis
Stratification by patient characteristic
Participants will be stratified according to three indica-
tions for treatment: simple lengthening, lengthening with
deformity correction, and soft tissue correction. The
amount of lengthening anticipated will be calculated both
as an absolute value in cm as well as a percentage of the
length of the bone to be lengthened. Amount of deformity
correction will be calculated in number of degrees. Partic-
ipants will be stratified to two categories according to the
severity of the limb length discrepancy or deformity cor-
rection: < 20% or > 20% of the pre-operative values.
Potential Confounding Variables and Other Measurements
Information on infections will be recorded. All relevant
concomitant medications will be recorded. These varia-
bles will be considered in exploratory analyses.
2. Randomization
The randomization occurs at each site according to the
procedure successfully used during the pilot. The bio-stat-
istician consultant will generate a computerized block
randomization schedule for each site ensuring an equal
number of subjects in each group at each site. The coordi-
nating site will provide each site with a set of sealed enve-
lopes containing the randomization code for each patient,
which will be opened only by the individual preparing the
syringe. The patients will be randomly assigned to either
the treatment group or the placebo group. Concealment
of randomization will be enforced, so that individuals
enrolling patients will be unaware of whether the next
patient will be randomized to treatment or control
[73,74].
3. Masking
As the injection will be done intraoperatively, the patient
will be blinded. The treating surgeon will be given a
syringe for the injection and the surgeon will not know
whether the syringe contains BTX-A or placebo. Parents,
nursing staff, research, and rehabilitation staff are also
blinded to group assignment. All the personnel involved
in the assessments and analysis of the data will be
blinded. Only the pharmacy or OR nurse preparing the
syringe is aware of the group assignment.
5. Ethical Approval
Ethical approval was obtained from Shriners Hospital for
Children Headquarters Medical Research Office and from
6 local Institutional Review Board (IRB). The research pro-
posal will be explained to the patient and his or her fam-
ily. Signed informed consent and assent will be obtained.
6. BTX-A Injection Protocol
i. Timing of the injections
The surgical procedure will be performed in the usual
manner. The injection will be performed intraoperatively
under general anaesthesia at the conclusion of the surgical
procedure just prior to extubation to avoid any potential
effects of the depolarizing agents used at the time of
induction. BTX-A will be given only once (during the sur-
gery) and will not be repeated. The advantages of giving
the injection during the surgery (versus before or after) are
twofold: First it will allow the analgesic action of BTX-A to
take effect immediately (which is desired), while the par-Trials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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alytic action of BTX-A will take about 7 to 10 days to take
effect (coinciding with the start of distraction). Second,
the patient will be blinded and will not know whether he
has or has not received the injection.
ii. Dosage
- The dosage will be 10 units per Kg. not to exceed 400
Units
- The maximum will be 50 units per injection site
- Maximum dose of 5 Units/kg per large muscle group not
to exceed 200 Units
- Maximum volume of 1 ml per injection site
- Dilution is 100 units per ml.
This dosage is recommended by the FDA and is within the
accepted range recommended by Shriners Botox Task
Force as well as the American Academy of Cerebral Palsy
and Developmental Medicine. Although some authors
have used higher doses of BTX-A, we believe that higher
doses may weaken the muscles such as rehabilitation and
early weight bearing might become a problem, thus
defeating the purpose of the injections.
iii Dosage Calculation
Calculate maximum dose allowed according to child's
weight. For example, a 40 kg patient could receive the
maximum dose of 400 units.
iv: Number and location of Injection Sites
Calculate the number of injection sites according to the
maximum dose distributed. Agent will be injected into the
bellies of the muscle groups adjacent to the bone length-
ened according to the following guidelines. Diagrams for
anatomical location are included in study manual.
Femoral Lengthening:
Quadriceps muscle group: (max 200 Units)/50 Uper site
= 4 sites
1. Vastus Medialis (1)
2. Vastus Lateralis (1)
3. Vastus Intermedius/Rectus Femoris (2)
Hamstrings muscle group: (max 200 Units)/50 Uper site
= 4 sites
1. Medial Hamstrings (4)
Tibial Lengthening/Correction:
Gastrocsoleus Muscle group: (max 200 Units)/50 Uper
site = 4 sites
1. Gastrocnemius (2)
2. Soleus (2)
Clubfoot correction:
Gastrocsoleus Muscle group (max 200 Units)/50 Uper site
= 4 sites
1. Gastrocnemius (2)
2. Soleus (2)
7. Adverse Events
All serious adverse experiences will be reported. Minor
adverse events and unusual complications encountered
during the lengthening and or correction process will be
carefully recorded. Side effects include a flu-like syndrome
that is generally short-lived, dysphagia, and dry mouth.
Unintended weakness of the muscle injected or of nearby
muscles could also be a negative effect. Other side effects
include muscle soreness, rash, headaches, light-headed-
ness, fever, chills, hypertension, diarrhea and abdominal
pain.
In the event of a serious adverse reaction to the treatment
the patient will be treated accordingly depending on the
reaction. The following events will cause immediate cessa-
tion of the study.
1. Death
2. Upper limb paralysis or weakness
3. Bulbar weakness
a. Blurred vision
b. Facial paralysis
c. Dysarthria
4. Anaphylactic reaction
5. Any severe ADR
Unblinding of the patient will be carried out immediately.
The event will be analyzed in the same manner as any
severe ADR. This will be reported to the appropriate agen-
cies with the analysis, conclusions and recommendations.Trials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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The study will then be re-instituted if given approval to
continue. This patient will be categorized as a treatment
failure and assigned (imputed) the most negative score on
all outcomes.
8. Pain Management Protocol
Pain management (assessment and treatment) guidelines
are described in the study manual. Post operative pain
medication is delivered via either PCA or epidural up to
72 h post-op. Pain assessment will be done using a 10
point scale (either Faces Pain Scale revised or the Numer-
ical Rating Scale) according to post-operative PCA proto-
cols; hourly for first 4 hours, every 2 hours for next 8
hours, and every 4 hours once stable. After the PCA/epi-
dural is discontinued, PRN medications will be ordered
for pain control, nausea/vomiting, itching, and fever dur-
ing hospitalization. Pain assessments will also be done
whenever a patient receives a PRN medication. All of this
data will be recorded in the patient's chart along with the
medication dosages administered.
9. Post operative Activity and Rehabilitation Regimes
Patients will stay in hospital for 4–7 days following appli-
cation of the external fixator and administration of the
botox/placebo and until they are independent with the
turnings. During this period patients will follow the pain
management guidelines suggested for this group. All
patients will also be seen by a physical therapist for a
standardized exercise regime. During the distraction
phase patients will be followed in clinic on a biweekly
basis and during the consolidation phase on a monthly
basis. The children will continue to be followed for three
months after the external fixator is removed. Pain man-
agement, physical therapy, radiographs and adverse event
assessment will continue during the entire lengthening
process. Physical therapy and pain protocols are outlined
in a study manual.
10. Data Safety and Monitoring Committee (DSMC)
A Data and Safety Monitoring Committee (DSMC), con-
sisting of two experts in orthopedics and one biostatisti-
cian, will be constituted of experts with no vested interest
in the trial. The DSMC will be responsible for supervision
of the interim analysis, monitoring of the trial, and review
of all adverse events. The study will be stopped if the
interim analysis shows statistically significant results.
The study is blinded to the physician and assessors of out-
comes. The pharmacist at each center is responsible to
track each patient in the study, record which medication
was injected, and the clinical staff will record any adverse
effects noted. A standard data collection sheet will list
each patient, the dosage given and any adverse outcomes.
The information will be collected concurrently during the
immediate post-injection period with each local co-inves-
tigator informed of any adverse effects. For safety, the
investigators at each participating center will have
access to which medication is injected if treatment of an
acute adverse event is necessary. They will update the
information to the PI on a weekly basis as needed. The PI
and clinical staff are responsible for monitoring patient
safety by tracking and collating the data from all partici-
pating centers. All adverse effects will be reported to the
appropriate oversight committees (local IRB and FDA).
The PI is responsible to communicate these findings and
any changes in protocol as needed to the co-investigators.
11. Outcome Assessment
The outcome measures selected for the study relate
directly to the specific aims of the project. The data col-
lected will provide information on the pain scores, medi-
cation dosages, range of motion, flexibility, strength,
mobility function, and quality of life of the patient popu-
lation under study. Additional data will be collected on
the patient demographics, musculoskeletal information,
impact on the family during the distraction process, and
motivation of the child. During the pilot study the partic-
ipating hospitals finalized the selection of the outcome
tools, the data collection forms of physiotherapy and
nursing, as well as the timing of administration. The
research coordinator at each site will ensure that the time-
line is respected.
The measures will be administered pre-lengthening, pre-
distraction, mid-distraction, end distraction, mid-consoli-
dation, pre-frame removal and 3 months post-frame
removal. Pain scores, medication dosages and compliance
to physical therapy will be recorded daily during admis-
sion and throughout the distraction/consolidation proc-
ess. A timeline as shown in Table 1 will indicate when the
different variables will be measured and which tool is
given at which phase of the process. The time required to
complete the assessments is 20–30 minutes.
Standardized assessments chosen have been validated and
are reliable. The outcome measures are described below.
The Numerical Rating Scale (NRS) is a reliable and valid
tool that is widely used in pediatric centers as a measure
of acute pain. The Faces Pain Scale-Revised is a reliable
and valid pain scale for younger children. These tools will
be used by nursing to assess postoperative pain during the
first 5–7 days following surgery. The same scale will be
used by physiotherapists to assess pain pre and post-phys-
iotherapy treatment. In addition patients will be familiar
with these scales and will use them to rate their pain in a
Pain/Medication/PT compliance journal throughout the
study. The NRS has been translated into several languages.
Guidelines accompany both the NRS and Faces PainTrials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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Scale-Revised ensuring that they are administered in a uni-
form fashion [75].
Medication dosages are extracted from the inpatient
medical record and recorded on custom data collection
forms. The pain scores from the inpatient and outpatient
period are also transcribed to this form.
The Adolescent Pediatric Pain Tool (APPT) is a three part
tool which includes a visual analogue scale, a listing of 42
words that describe pain qualitatively and body diagrams
to localize the pain. Its validity and reliability have previ-
ously been established. Furthermore, this tool was previ-
ously used in the only other study on pain during
treatment of limb length discrepancy [15,76,77] The
APPT will be administered at the key pre-determined
intervals to measure the current, pain underlying the
lengthening procedure and in particular during the dis-
traction phase.
The  active and passive range of motion (ROM) of
involved joints will be measured using a goniometer
according to the Shriners Hospital for Children Motion
Analysis Lab ROM protocols in order to evaluate the effect
of BTX-A on muscle spasm and muscle contracture (Spe-
cific aim 2). Measurement will be recorded by the treating
physical therapist as of post-op day 2, continuing daily
until discharge, weekly during distraction and monthly
during consolidation. Standard flexibility tests using
measurements of angles will also be recorded. Strength
will be measured by active movement and by the extent of
the quads lag at baseline and at 3 months post frame
removal.
The  Gillette Functional Assessment Questionnaire
(FAQ) was developed by the Gillette Children's Specialty
Healthcare to measure ambulation status. The pre-op ver-
sion includes a 10-level parent report walking scale, need
for assistive devices, and lists to describe limits to walking
and additional activities commonly performed in the
standing position. The walking scale only will be admin-
istered according to the timeline. The inter and intra rater
reliability of the walking scale has previously been dem-
onstrated as well it is sensitive to changes in orthopedic
conditions.
The Pediatric Quality of Life Inventory (PedsQL) is a 23-
item questionnaire developed by Dr. J. Varni at the Center
for Child Health Outcomes at the Children's Hospital and
Health Care Center, San Diego. According to the authors,
the PedsQL measures health related quality of life in
healthy children and children with health conditions. The
generic module which consists of four domains: physical
health, emotional, social, and school, as well the pain sec-
tion (4 items) of the rheumatology module, will be
administered to assess quality of life during the lengthen-
ing or correction process. The PedsQL has a parent and
child version for five different age groups and so measures
both perspectives of the impact of the procedure. It is self-
administered and has been translated into French and
Spanish. Completion requires 10 minutes. The PedsQL
has proven reliability and validity and can distinguish
between healthy children and those with health condi-
tions. [78].
The Impact on Family Scale (IOF) is a 27-item inventory
translated into French and Spanish that takes approxi-
mately 10 minutes to complete and measures a parent's
perception of the effects of the child's ongoing health con-
dition on family life. The IOF will measure the amount of
stress and disequilibrium experienced by the family of the
child undergoing the painful and long lengthening or cor-
rection. It will be administered at the end of the process.
It is not disease specific and can be used with minimal
training. The measure has been widely used since 1980
and has good face validity. It has recently undergone a
revised scoring procedure and additional psychometric
tests showing that it is a reliable and valid measure [79].
The Dimensions of Motivation Questionnaire (DMQ-
17) was developed by Morgan, Maslin-Cole, Biringen and
Harmon to measure motivation, a multi-faceted, intrinsic
psychological force that stimulates an individual to
attempt to master a skill or task that is at least moderately
challenging for him. The DMQ was recently revised to
include all ages of children. It consists of a 45-item ques-
tionnaire of 5 scales: object oriented persistence, social/
symbolic persistence, gross motor persistence, mastery
pleasure, and general competence. The DMQ will measure
a child's underlying motivation to determine what role it
may play in the outcome of lengthenings. The recent re-
scoring of the DMQ has produced a conceptually stronger
and psychometrically stronger questionnaire [80,81].
A Pain/Medication/PT Compliance Journal will record
the amount of analgesic medication required daily (dos-
age, frequency, time), pain experienced and compliance
to Physical Therapy home exercise program during the
outpatient period. The family will be provided with a cus-
tomized booklet for this purpose.
Radiographs will be obtained during the process to assess
the amount of lengthening, state of new bone formation,
quality of the regenerate, and development of osteopenia.
12. Standardization
A study manual was prepared based on the experience
gained from the pilot work, which outlines the protocols
for assessments; injection, therapy, and pain manage-
ment. The manual was discussed at the face-to-face meet-Trials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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ings in 2005. Consensus was reached on key points and it
was revised in December 2005
Regular conference calls and an annual meeting are
planned to further ensure consistency across sites.
Individual patient tracking sheets ensure that data collec-
tion is complete at each time point.
13. Data Management
All data will be kept confidential using a coding system
unique to each hospital. With the input of a medical infor-
mation specialist from headquarters, a collaborative
research site will be established on the Shriners intranet
system to facilitate an electronic interface for data collec-
tion and data transfer.
Pain scores and medication dosages will be extracted from
the medical record and transferred to a customized data
collection form available on the intranet site. Hospitals
will send the data collection forms by courier to the
project manager at the Montreal Hospital where trained
personnel will enter all the data into the Access database.
Paper copies of the questionnaires will record the perti-
nent scores and the completed questionnaires (identified
by study number only) will be sent by courier to the lead
hospital and treated similarly.
This database will include some validation processes to
ensure the quality of the data. Any doubtful data will be
checked with the person responsible at the site where it
occurred, and changes to the database will be docu-
mented. A single person at the Lead hospital will do the
data entry to ensure reliability of the process. The data
analysis will be performed by bio-statistician consultants
to the project.
14. Statistical Analysis
Descriptive statistics will be calculated for all outcome
variables and all relevant baseline variables. The data will
be presented in summary tables, graphs, and listings to
give an overview of the outcome and efficacy findings. The
mean, median, standard deviation, and range of each var-
iable and its change from baseline, measured on a contin-
uous scale, will be presented by treatment and visit.
Frequency tables will be provided for categorical variables
by treatment and visit.
There are three primary outcomes: pain measured by the
FPS-r or NRS, requirements of pain medication, and the
quality of life using the PedsQL. The primary analysis for
the pain will be performed during the post-operative (5–
10 days) period as well as the mid-distraction phase. The
primary analysis for the pediatric quality of life will be
performed at mid-distraction and the mid-consolidation
phase before the removal of the fixator. The primary anal-
ysis will be conducted using T-tests for continuous varia-
bles and chi-square and Fisher exact tests for categorical
variables.
An interim analysis will be performed when 75 patients
(1/2 the estimated sample size) have been enrolled, using
the Obrien-Fleming group-sequential stopping rule.
[82,83]
Primary statistical hypotheses
￿ Pain scores will be less, in those who received BTX-A,
during the 5–10 days post-operative period compared to
those who received saline injections (Specific aim 1).
￿ Pain scores will be less, in those who received BTX-A, at
mid-distraction compared to those who received saline
injections (Specific aim 1).
￿ The total amount of narcotic pain medication during the
10 days post-operative will be lower in those patients who
received BTX-A than in those who received saline injec-
tions.
￿ Quality of life scores during mid-distraction will be
higher in those who received BTX-A compared to those
who received saline injections (Specific aim 2).
￿ Range of motion measurements and mobility scores will
be improved in those who received BTX-A compared to
those who received saline injections (Specific aim 3).
Primary Outcome Measures: FPS-r/NRS, PedsQL, ROM
Secondary Analysis
Secondary longitudinal analyses will be carried out and
include several time periods and compare additional var-
iables as shown in the following table. Stratification by
age or site of fixator or type of surgery (lengthening versus
correction) will allow further analyses. T-tests and analy-
ses by repeated measures will be used for the secondary
analyses.
Sample size
The proposed sample size of 75 per group provides 80%
power to detect an effect size of 0.45, with alpha = 0.05.
The effect size of 0.45 corresponds to a difference of
approximately 7.5 in the PedsQL (Ref Varni et al 2002,
Varni et al 2003). This difference is smaller than that
found in studies comparing children with chronic dis-
eases to healthy children. The following table provides a
range of options for sample size, using the PedsQL as an
example. For a standard deviation (SD) of 15 and alpha
(type I error) of 0.05, the power is as given in the first col-
umn for different values of delta (the detectable differenceTrials 2007, 8:27 http://www.trialsjournal.com/content/8/1/27
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between the groups). The differences detected in the pilot
work support the planned sample size.
Discussion
The global aim of this proposal is to determine if BTX-A
can alleviate the post-operative pain and improve the
functional outcome of children undergoing limb length-
ening or deformity correction.
We have decided to measure in the post op period both
the total amount of pain as well as the total amount of
narcotics since both parameters are interconnected. Some
patients may have very little pain but on the other hand
may have received large doses of narcotics, therefore it is
important to measure and record both parameters.
The mobility variables, weight bearing, range of motion
and level of ambulation are indicative of a higher level of
participation. In addition, an increased level of mobility is
associated with lengthenings that have fewer complica-
tions such as delayed healing.
Reduced pain and increased mobility are felt to contribute
to an improved quality of life for children undergoing
lengthening. Clearly, these key variables are linked during
the long and painful process of distraction osteogenesis
and botox may assist in initiating this process.
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